Latest Regulatory News

Buru Energy is actively pursuing funding for its 2026 drilling campaign to validate resources at the Rafael Gas Project, aiming for a Final Investment Decision in the second half of 2026 and first cashflow by 2028.

FireFly Metals has successfully raised approximately A$139 million through a multi-part equity raising, significantly bolstering its cash reserves to advance its flagship Green Bay Copper-Gold Project in Newfoundland. The company also closed its oversubscribed Share Purchase Plan early, reflecting strong investor demand.

Netwealth Group Limited will compensate members affected by the First Guardian Master Fund collapse with $101 million, impacting its 1H26 profit but aiming to restore member confidence swiftly.

Telix Pharmaceuticals confirms completion of Part 1 enrolment in its ProstACT Phase 3 trial for prostate cancer, with safety data supporting progression to Part 2 and regulatory approvals secured across multiple countries.

Equus Energy Limited launches a $15 million public offer to fund the acquisition and development of the Equus Gas Project in Western Australia, backed by conditional funding from Alcoa. The project boasts a large independently certified contingent gas resource, positioning the company to address looming supply shortfalls in domestic and LNG markets.

ActivEX Limited has raised $100,000 through a strategic share placement to Business Victor Investments, aiming to accelerate its exploration projects and strengthen working capital.

Tamawood Limited anticipates a substantial 40% to 50% increase in first-half FY26 profit before tax, driven by a 36.5% rise in sales and improved Work In Progress reporting confirmed by auditors.

DEXUS has announced an estimated ordinary distribution of AUD 0.193 per unit for the six months ending December 2025, marking a steady income stream for investors ahead of the new year.

Opthea Limited has announced a strategic pivot to develop OPT-302 for Lymphangioleiomyomatosis (LAM), a rare lung disease affecting women, aiming for ASX reinstatement in 2026. The company leverages strong intellectual property and cash reserves to pursue orphan drug designation and clinical development.

Humm Group has received a shareholder notice to remove key directors alongside a non-binding acquisition proposal from Credit Corp, signaling potential major changes ahead.

Neurotech International has locked in $4 million through a share placement to advance its promising paediatric neurological drug, NTI164. The raise, supported by both new and existing investors including company directors, aims to fund critical clinical and regulatory milestones.

Variscan Mines has secured government approval for its Preliminary Mining Plan, enabling critical pre-works and trial mining at the San Jose Mine in Spain. This milestone accelerates the company’s strategy to restart production with minimal capital expenditure.